MX2015014267A - Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de ganadotropina. - Google Patents

Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de ganadotropina.

Info

Publication number
MX2015014267A
MX2015014267A MX2015014267A MX2015014267A MX2015014267A MX 2015014267 A MX2015014267 A MX 2015014267A MX 2015014267 A MX2015014267 A MX 2015014267A MX 2015014267 A MX2015014267 A MX 2015014267A MX 2015014267 A MX2015014267 A MX 2015014267A
Authority
MX
Mexico
Prior art keywords
diseases
gonadotropin
receptor antagonists
releasing hormone
spiroindoline derivatives
Prior art date
Application number
MX2015014267A
Other languages
English (en)
Inventor
Stefan BÄURLE
Reinhard Nubbemeyer
Olaf Panknin
Sven Ring
Katrin Nowak-Reppel
Gernot Langer
Andrea Wagenfeld
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48047908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015014267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2015014267A publication Critical patent/MX2015014267A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Derivados de espiroindolina, procesos para su preparación y composiciones farmacéuticas con los mismos, su uso para el tratamiento de enfermedades y su uso en la elaboración de medicamentos para el tratamiento de enfermedades, en especial enfermedades relacionadas con las hormonas sexuales, tanto en hombres como en mujeres, en particular aquellas seleccionadas del grupo de endometriosis, leiomioma uterino (fibroides), enfermedad de ovario poliquístico, menorragia, dismenorrea, hirsutismo, pubertad precoz, neoplasias dependientes de esteroides gonadales tales como cánceres de próstata, de mama y de ovario, adenomas pituitarios gonadotrópicos, apnea del sueño, síndrome de intestino irritable, síndrome premenstrual, hipertrofia prostática benigna, anticoncepción, esterilidad y terapia de reproducción asistida tal como la fertilización in vitro. La presente solicitud se relaciona en particular con derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina (GnRH). (ver Fórmula).
MX2015014267A 2013-04-09 2014-04-08 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de ganadotropina. MX2015014267A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13162986 2013-04-09
PCT/EP2014/057079 WO2014166958A1 (en) 2013-04-09 2014-04-08 Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists

Publications (1)

Publication Number Publication Date
MX2015014267A true MX2015014267A (es) 2016-03-01

Family

ID=48047908

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015014267A MX2015014267A (es) 2013-04-09 2014-04-08 Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de ganadotropina.

Country Status (28)

Country Link
US (1) US20160052936A1 (es)
EP (1) EP2984092A1 (es)
JP (1) JP2016519104A (es)
KR (1) KR20150139917A (es)
CN (1) CN105308053A (es)
AP (1) AP2015008822A0 (es)
AR (1) AR095785A1 (es)
AU (1) AU2014253232A1 (es)
BR (1) BR112015025700A2 (es)
CA (1) CA2908869A1 (es)
CL (1) CL2015003013A1 (es)
CR (1) CR20150530A (es)
CU (1) CU20150141A7 (es)
DO (1) DOP2015000259A (es)
EA (1) EA201501000A1 (es)
HK (1) HK1216101A1 (es)
IL (1) IL241067A0 (es)
MA (1) MA38463B1 (es)
MX (1) MX2015014267A (es)
NI (1) NI201500149A (es)
PE (1) PE20160007A1 (es)
PH (1) PH12015502318A1 (es)
SG (1) SG11201506962TA (es)
TN (1) TN2015000453A1 (es)
TW (1) TW201518304A (es)
UY (1) UY35526A (es)
WO (1) WO2014166958A1 (es)
ZA (1) ZA201508209B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018224498A1 (en) 2017-06-05 2018-12-13 ObsEva S.A. Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213715D0 (en) * 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
PE20141699A1 (es) * 2012-01-16 2014-11-29 Bayer Ip Gmbh Derivados de espiroindolina como antagonistas del receptor de la hormona liberadora de gonadotropina

Also Published As

Publication number Publication date
CN105308053A (zh) 2016-02-03
EP2984092A1 (en) 2016-02-17
MA38463A1 (fr) 2018-05-31
NI201500149A (es) 2015-11-30
EA201501000A1 (ru) 2016-04-29
TN2015000453A1 (en) 2017-04-06
IL241067A0 (en) 2015-11-30
PH12015502318A1 (en) 2016-02-15
TW201518304A (zh) 2015-05-16
SG11201506962TA (en) 2015-10-29
AR095785A1 (es) 2015-11-11
US20160052936A1 (en) 2016-02-25
JP2016519104A (ja) 2016-06-30
PE20160007A1 (es) 2016-02-14
BR112015025700A2 (pt) 2017-07-18
AP2015008822A0 (en) 2015-10-31
HK1216101A1 (zh) 2016-10-14
WO2014166958A1 (en) 2014-10-16
CA2908869A1 (en) 2014-10-16
UY35526A (es) 2014-11-28
DOP2015000259A (es) 2015-11-15
KR20150139917A (ko) 2015-12-14
CL2015003013A1 (es) 2016-04-08
ZA201508209B (en) 2018-05-30
MA38463B1 (fr) 2018-11-30
CU20150141A7 (es) 2016-03-31
CR20150530A (es) 2016-01-29
AU2014253232A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
TN2014000306A1 (en) Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists
IN2012DN05082A (es)
JO3009B1 (ar) مشتقات 17-هيدروكسي-17بنتافلوروإيثيل-إسترا-4،9(10)-دين-11-أريل، طريقة لإنتاجها واستخدامها في معالجة الأمراض
MX2023002450A (es) Formulaciones farmaceuticas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico o la adenomiosis.
JP2014503537A5 (es)
BR112014021331A8 (pt) Antagonistas do receptor do hormônio liberador de gonadotropina, composição farmacêutica compreendendo os mesmos e uso desses
MX2023002449A (es) Formulaciones farmaceuticas solidas para tratar la endometriosis, los fibromas uterinos, el sindrome de ovario poliquistico y la adenomiosis.
TN2013000501A1 (en) Neutralizing prolactin receptor antibody mat3 and its therapeutic use
TN2012000618A1 (en) 6,7-dihydro-5h-benzo[7]annulene derivatives, process for preparation thereof, pharmaceutical preparations comprising them, and the use thereof for production of medicaments
PH12015502318A1 (en) Spiroindoline derivatives for use as gonadotropin-releasing hormone receptor antagonists
NZ602525A (en) Compositions and methods for non-toxic delivery of antiprogestins
MX2009009514A (es) Heterociclos sulfonilados utiles para la modulacion del receptor de progesterona.
PH12015502326A1 (en) Progesterone receptor antagonist dosage form
AR096905A1 (es) Derivados de espiroindolina y composiciones farmacéuticas de los mismos
NZ612295A (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
BR9911564A (pt) Composto, processo para produzir um composto, composição farmacêutica, processo para antagonizar o hormÈnio de liberação de gonadotropina em um mamìfero, e, uso de um composto
TN2011000022A1 (en) Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a - ring
GB2514958A (en) Drug delivery system for finasteride to prostate